跳转至内容
Merck
CN
  • Preemptive thoracic drainage to eradicate postoperative pulmonary complications after living donor liver transplantation.

Preemptive thoracic drainage to eradicate postoperative pulmonary complications after living donor liver transplantation.

Journal of the American College of Surgeons (2014-12-03)
Daisuke Imai, Toru Ikegami, Takeo Toshima, Tomoharu Yoshizumi, Yo-ichi Yamashita, Mizuki Ninomiya, Norifumi Harimoto, Shinji Itoh, Hideaki Uchiyama, Ken Shirabe, Yoshihiko Maehara
摘要

Thoracic fluid retention after living donor liver transplantation (LDLT) has various negative consequences, including atelectasis, pneumonia, and respiratory distress or failure. We analyzed the clinical impact of preemptive thoracic drainage in 177 patients undergoing adult-to-adult LDLT for chronic liver diseases at a single center. Recipients were divided into 2 time periods. The earlier cohort (n = 120) was analyzed for risk factors for postoperative atelectasis retrospectively; the later cohort (n = 57), with a risk factor for postoperative atelectasis, underwent preemptive thoracic drainage prospectively. The incidence of postoperative pulmonary complications was compared between these 2 cohorts. Independent risk factors for atelectasis in earlier cohort were body mass index ≥27 kg/m(2) (p < 0.001), performance status ≥3 (p = 0.003) and model for end-stage liver disease score ≥23 (p = 0.005). The rates of atelectasis (21.1% vs 42.5%, p = 0.005) and pneumonia (1.8% vs 10.0%, p = 0.049) were significantly lower in later than in earlier cohort. Moreover, the mean durations of ICU stay (3.6 ± 0.2 days vs 5.7 ± 0.6 days, p = 0.038) and postoperative oxygen support (5.1 ± 0.8 days vs 7.1 ± 0.5 days, p = 0.037) were significantly shorter in the later than in the earlier cohort. There were no significant differences in the incidence of adverse events associated with thoracic drainages between these 2 cohorts. Preemptive thoracic drainage for transplant recipients at high risk of postoperative atelectasis could decrease morbidities after LDLT.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
FK-506 一水合物, ≥98% (HPLC)
USP
他克莫司, United States Pharmacopeia (USP) Reference Standard
USP
霉酚酸酯, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
(±)-CPP, solid
霉酚酸酯, European Pharmacopoeia (EP) Reference Standard
吗替麦考酚酯, European Pharmacopoeia (EP) Reference Standard